SIRPA and anemia: Because of the high expression of CD47 in erythrocytes, the major side effect of clinical application of anti-CD47 antibodies and CD47-targeting SIRPα-Fc fusion protein is anemia due to CD47-mediated phagocytosis of erythrocytes45–47.